Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06014502 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

A Phase 1 study of Solid Tumor, sponsored by ImmunoGenesis.

Recruiting
Registry status
Phase 1
Development phase
105
Enrollment target
5
Study locations

NCT06014502: Recruiting Phase 1 study of Solid Tumor, sponsored by ImmunoGenesis.

NCT06014502 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by ImmunoGenesis. The registered enrollment target is 105 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (52% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06014502, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by ImmunoGenesis.

RECRUITING
Registry status
Phase 1
Development phase
105 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following treatment with other available therapies will be treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to further determine the safety and potential effectiveness in select cancer types.

Primary Outcome

Frequency and severity of dose limiting toxicities and adverse events

Conditions Studied

Interventions

  • DRUG IMGS-001

Study Locations (5)

Texas

  • MD Anderson Cancer Center - Houston
  • NEXT Dallas - Irving

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

California

  • Sarcoma Oncology Center - Santa Monica

Louisiana

  • Ochsner Clinic Foundation - New Orleans

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2023-09-07
Est. Completion 2027-12
Phase Phase 1
ImmunoGenesis

8 total trials

What NCT06014502 shows while recruiting

NCT06014502 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (52% lower).

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMGS-001 is the first listed.

NCT06014502 lists 5 locations in 4 states (Texas, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT06014502 about?

NCT06014502 is a clinical study titled "Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors". The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their ...

What is the current status of trial NCT06014502?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2023-09-07. Estimated completion is 2027-12.

What conditions does trial NCT06014502 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT06014502?

The interventions under investigation include: IMGS-001 (DRUG).

Who is sponsoring clinical trial NCT06014502?

This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06014502 being conducted?

This trial has 5 study locations across Arizona, California, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06014502's enrollment target sits among peer trials

105 83rd of 196 higher than 114 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06014502, the US trial registry maintained by the National Library of Medicine. NCT06014502 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.